uniQure (NASDAQ:QURE) Trading Down 3.5% – Here’s What Happened

Shares of uniQure (NASDAQ:QURE) dropped 3.5% during trading on Monday . The stock traded as low as $17.21 and last traded at $17.32. Approximately 85,917 shares were traded during mid-day trading, a decline of 86% from the average daily volume of 603,523 shares. The stock had previously closed at $17.94.

Analyst Ratings Changes

A number of brokerages have recently weighed in on QURE. HC Wainwright restated a “buy” rating and set a $25.00 price objective on shares of uniQure in a research report on Tuesday, December 10th. Stifel Nicolaus lifted their price objective on uniQure from $12.00 to $32.00 and gave the stock a “buy” rating in a research note on Monday, December 16th. The Goldman Sachs Group raised their target price on shares of uniQure from $9.00 to $20.00 and gave the company a “neutral” rating in a report on Thursday, December 12th. Leerink Partners boosted their target price on shares of uniQure from $26.00 to $44.00 and gave the stock an “outperform” rating in a report on Wednesday, December 11th. Finally, Guggenheim restated a “buy” rating on shares of uniQure in a report on Wednesday, December 11th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, six have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, uniQure presently has a consensus rating of “Moderate Buy” and a consensus target price of $33.88.

uniQure Stock Down 9.8 %

The company has a market cap of $775.99 million, a P/E ratio of -3.21 and a beta of 0.41. The business’s fifty day moving average is $10.83 and its two-hundred day moving average is $7.85. The company has a debt-to-equity ratio of 0.92, a quick ratio of 6.51 and a current ratio of 6.51.

uniQure (NASDAQ:QURE) last issued its earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share for the quarter, topping the consensus estimate of ($1.12) by $0.21. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. The business had revenue of $2.29 million during the quarter, compared to analysts’ expectations of $2.73 million. Equities analysts predict that uniQure will post -3.82 EPS for the current year.

Insider Activity

In related news, CEO Matthew C. Kapusta sold 3,418 shares of uniQure stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $7.63, for a total value of $26,079.34. Following the completion of the sale, the chief executive officer now directly owns 597,915 shares in the company, valued at $4,562,091.45. This trade represents a 0.57 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 4.74% of the company’s stock.

Institutional Investors Weigh In On uniQure

Institutional investors and hedge funds have recently made changes to their positions in the stock. Doheny Asset Management CA purchased a new stake in uniQure during the 2nd quarter valued at about $1,220,000. American Century Companies Inc. increased its holdings in uniQure by 14.6% in the 2nd quarter. American Century Companies Inc. now owns 67,699 shares of the biotechnology company’s stock worth $303,000 after buying an additional 8,642 shares during the period. Total Clarity Wealth Management Inc. acquired a new stake in uniQure during the 2nd quarter valued at approximately $74,000. Vanguard Personalized Indexing Management LLC boosted its holdings in shares of uniQure by 21.0% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 13,301 shares of the biotechnology company’s stock valued at $59,000 after acquiring an additional 2,306 shares during the last quarter. Finally, Marshall Wace LLP purchased a new position in shares of uniQure during the second quarter worth $175,000. 78.83% of the stock is currently owned by institutional investors and hedge funds.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.